2021 Webinar: Genetics of NAFLD-Genetics of NAFLD

Video Transcription

Video Summary

The webinar provided an overview of genetic variants that have been associated with non-alcoholic fatty liver disease (NAFLD). The first speaker discussed the heritability of NAFLD, which is estimated to be between 20% and 50%, and highlighted the complexity and variability of the disease. Several genetic variants were discussed, including PNPLA3, TM6SF2, MBOAT7, and HSD17B13. These variants have been associated with different aspects of NAFLD, such as liver fat accumulation, inflammation, fibrosis, and hepatocellular carcinoma. The speaker also emphasized the need for further research to better understand the underlying molecular mechanisms and pathways involved in NAFLD. The second speaker explored the role of specific variants in humans with NAFLD and highlighted the associations between these variants and the severity of the disease as well as outcomes such as fibrosis and hepatocellular carcinoma. The third speaker discussed the therapeutic options and clinical implications of genetic risk variants for NAFLD. They focused on the potential use of targeted therapies, such as PNPLA3 silencing, for individuals at high risk of developing liver-related complications. The speaker also highlighted the importance of genetic risk scores and their potential use for predicting the risk of liver progression in patients with NAFLD. Overall, the webinar provided valuable insights into the genetic factors influencing NAFLD susceptibility and progression, and the potential for targeted therapies based on these genetic variants.

Keywords

genetic variants

non-alcoholic fatty liver disease

NAFLD

PNPLA3

TM6SF2

MBOAT7

HSD17B13

fibrosis

targeted therapies